Sweeping structural changes and scientific breakthroughs are driving
demand for new products, services and technologies
Ambit Biosciences Corp. is a biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for the treatment of cancer. With more than 500 distinct kinases identified and over 30 kinase inhibitors in clinical trials or FDA approved, this important class of proteins is a rich area for therapeutic drug development.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a biotechnology company developing small-molecule, orally-active drugs, known as Pharmacological Chaperones for treating human genetic disorders. Pharmacological chaperones are designed to help mutant proteins fold correctly into their normal 3-dimensional conformations, rescuing intrinsic biological activity and function.
Athersys, Inc. (NASDAQ:ATHX) is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing MultiStem, a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. The Company is also developing a portfolio of other therapeutic programs, including orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders.
Resolvyx Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Initial indications include, among others, asthma, rheumatoid arthritis, cardiovascular disease and multiple eye diseases.
Rib-X Pharmaceuticals, Inc. is a biotechnology company focused on the structure-based design of new classes of antibiotics. The company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the 50S subunit of the ribosome, which performs an essential role in the fundamental process of protein synthesis. Rib-X has multiple drug candidates in clinical and preclinical development targeting some of the leading causes of serious community and hospital-acquired infectious diseases.
Corus Pharma, Inc. was acquired by Gilead Sciences in August 2006. Prior to the acquisition, Corus was developing small molecule drugs for the treatment of respiratory diseases.